STOCK TITAN

[Form 4] INTUITIVE SURGICAL INC Insider Trading Activity

Filing Impact
(High)
Filing Sentiment
(Very Negative)
Form Type
4
Rhea-AI Filing Summary

Intuitive Surgical (ISRG) CEO David J. Rosa reported insider transactions on 10/24/2025. He exercised 27,000 non-qualified stock options at an exercise price of $79.6378 per share and sold 24,500 shares of common stock at a weighted average price of $547.5502.

The sales were executed under a Rule 10b5-1 trading plan that expires on June 11, 2026, with individual trade prices ranging from $542.16 to $550.21. Following these transactions, Rosa beneficially owns 234,256 shares directly. The exercised option, granted under the 2010 Incentive Award Plan, carries an expiration date of 02/15/2027 and vested per a stated schedule.

Intuitive Surgical (ISRG) il CEO David J. Rosa ha riportato operazioni di insider il 24/10/2025. Ha esercitato 27.000 stock option non qualificati a un prezzo di esercizio di $79.6378 per azione e ha venduto 24.500 azioni ordinarie a un prezzo medio ponderato di $547.5502.

Le vendite sono state eseguite nell'ambito di un piano di trading Rule 10b5-1 che scade il 11 giugno 2026, con prezzi delle singole contrattazioni che variano da $542.16 a $550.21. Dopo queste operazioni, Rosa detiene direttamente 234,256 azioni. L'opzione esercitata, concessa nell'ambito del 2010 Incentive Award Plan, ha data di scadenza 15/02/2027 ed è maturata secondo un programma previsto.

Intuitive Surgical (ISRG) el CEO David J. Rosa reportó transacciones de insider el 24/10/2025. Ejerció 27,000 opciones de compra no calificadas a un precio de ejercicio de $79.6378 por acción y vendió 24,500 acciones de acciones comunes a un precio medio ponderado de $547.5502.

Las ventas se ejecutaron bajo un plan de negociación Rule 10b5-1 que vence el 11 de junio de 2026, con precios de operación individuales que oscilan entre $542.16 y $550.21. Tras estas operaciones, Rosa posee beneficiosamente 234,256 acciones directamente. La opción ejercida, otorgada bajo el 2010 Incentive Award Plan, tiene una fecha de vencimiento de 15/02/2027 y vestía según un cronograma indicado.

Intuitive Surgical (ISRG)의 CEO 데이비드 J. 로사가 내부자 거래를 2025년 10월 24일에 보고했습니다. 그는 27,000주 비자격 주식매수선택권을 행사했고 행사가격은 $79.6378 달러, 보통주 24,500주가중평균가 $547.5502로 매도했습니다.

이 매각은 Rule 10b5-1 거래계획에 따라 이루어졌으며 이 계획은 2026년 6월 11일에 만료됩니다. 단건 거래 가격은 $542.16에서 $550.21 사이였습니다. 이 거래들 이후 로사는 직접적으로 234,256주 보유합니다. 행사된 옵션은 2010 Incentive Award Plan 아래에서 부여되었으며 만료일은 2027년 2월 15일이고 명시된 일정에 따라 귀속되었습니다.

Intuitive Surgical (ISRG) le PDG David J. Rosa a déclaré des transactions d’initié le 24/10/2025. Il a exercé 27 000 options d’achat non qualifiées à un prix d’exercice de $79,6378 par action et a vendu 24 500 actions ordinaires à un prix moyen pondéré de $547,5502.

Les ventes ont été réalisées dans le cadre d’un plan de trading Rule 10b5-1 qui expire le 11 juin 2026, avec des prix de transactions individuelles allant de $542,16 à $550,21. Suite à ces opérations, Rosa détient directement 234 256 actions en tant que bénéficiaire. L’option exercée, accordée dans le cadre du 2010 Incentive Award Plan, a une date d’expiration du 15/02/2027 et a vesté selon un calendrier indiqué.

Intuitive Surgical (ISRG) CEO David J. Rosa meldete Insider-Transaktionen am 24.10.2025. Er übte 27.000 nicht qualifizierte Aktienoptionen zu einem Ausübungspreis von $79.6378 pro Aktie aus und verkaufte 24.500 Stammaktien zu einem gewogenen Durchschnittspreis von $547.5502.

Die Verkäufe wurden im Rahmen eines Rule 10b5-1-Handelsplans durchgeführt, der am 11. Juni 2026 läuft, mit Einzelhandelspreisen zwischen $542.16 und $550.21. Nach diesen Transaktionen besitzt Rosa direkt 234,256 Aktien. Die ausgeübte Option, gewährt im Rahmen des 2010 Incentive Award Plan, hat ein Verfallsdatum von 15.02.2027 und war gemäß einem festgelegten Zeitplan vestet.

Intuitive Surgical (ISRG) رئيسها التنفيذي ديفيد ج. روزا أبلغ عن معاملات داخلية في 24/10/2025. قام بممارسة 27,000 خيار شراء غير مؤهل بسعر تنفيذ قدره $79.6378 لكل سهم وببيع 24,500 سهماً من الأسهم العادية بسعر $547.5502 المتوسط المرجح للسهم.

تم تنفيذ هذه المبيعات بموجب خطة تداول Rule 10b5-1 التي تنتهي في 11 يونيو 2026، وبأسعار صفقات فردية تتراوح بين $542.16 و$550.21. عقب هذه المعاملات، يملك روزا مباشرةً 234,256 سهماً من الأسهم. الخيار الممارس، الممنوح بموجب 2010 Incentive Award Plan، له تاريخ انتهاء 15/02/2027 ولم يفلس حسب الجدول المذكور.

Positive
  • None.
Negative
  • None.

Insights

Analyzing...

Intuitive Surgical (ISRG) il CEO David J. Rosa ha riportato operazioni di insider il 24/10/2025. Ha esercitato 27.000 stock option non qualificati a un prezzo di esercizio di $79.6378 per azione e ha venduto 24.500 azioni ordinarie a un prezzo medio ponderato di $547.5502.

Le vendite sono state eseguite nell'ambito di un piano di trading Rule 10b5-1 che scade il 11 giugno 2026, con prezzi delle singole contrattazioni che variano da $542.16 a $550.21. Dopo queste operazioni, Rosa detiene direttamente 234,256 azioni. L'opzione esercitata, concessa nell'ambito del 2010 Incentive Award Plan, ha data di scadenza 15/02/2027 ed è maturata secondo un programma previsto.

Intuitive Surgical (ISRG) el CEO David J. Rosa reportó transacciones de insider el 24/10/2025. Ejerció 27,000 opciones de compra no calificadas a un precio de ejercicio de $79.6378 por acción y vendió 24,500 acciones de acciones comunes a un precio medio ponderado de $547.5502.

Las ventas se ejecutaron bajo un plan de negociación Rule 10b5-1 que vence el 11 de junio de 2026, con precios de operación individuales que oscilan entre $542.16 y $550.21. Tras estas operaciones, Rosa posee beneficiosamente 234,256 acciones directamente. La opción ejercida, otorgada bajo el 2010 Incentive Award Plan, tiene una fecha de vencimiento de 15/02/2027 y vestía según un cronograma indicado.

Intuitive Surgical (ISRG)의 CEO 데이비드 J. 로사가 내부자 거래를 2025년 10월 24일에 보고했습니다. 그는 27,000주 비자격 주식매수선택권을 행사했고 행사가격은 $79.6378 달러, 보통주 24,500주가중평균가 $547.5502로 매도했습니다.

이 매각은 Rule 10b5-1 거래계획에 따라 이루어졌으며 이 계획은 2026년 6월 11일에 만료됩니다. 단건 거래 가격은 $542.16에서 $550.21 사이였습니다. 이 거래들 이후 로사는 직접적으로 234,256주 보유합니다. 행사된 옵션은 2010 Incentive Award Plan 아래에서 부여되었으며 만료일은 2027년 2월 15일이고 명시된 일정에 따라 귀속되었습니다.

Intuitive Surgical (ISRG) le PDG David J. Rosa a déclaré des transactions d’initié le 24/10/2025. Il a exercé 27 000 options d’achat non qualifiées à un prix d’exercice de $79,6378 par action et a vendu 24 500 actions ordinaires à un prix moyen pondéré de $547,5502.

Les ventes ont été réalisées dans le cadre d’un plan de trading Rule 10b5-1 qui expire le 11 juin 2026, avec des prix de transactions individuelles allant de $542,16 à $550,21. Suite à ces opérations, Rosa détient directement 234 256 actions en tant que bénéficiaire. L’option exercée, accordée dans le cadre du 2010 Incentive Award Plan, a une date d’expiration du 15/02/2027 et a vesté selon un calendrier indiqué.

Intuitive Surgical (ISRG) CEO David J. Rosa meldete Insider-Transaktionen am 24.10.2025. Er übte 27.000 nicht qualifizierte Aktienoptionen zu einem Ausübungspreis von $79.6378 pro Aktie aus und verkaufte 24.500 Stammaktien zu einem gewogenen Durchschnittspreis von $547.5502.

Die Verkäufe wurden im Rahmen eines Rule 10b5-1-Handelsplans durchgeführt, der am 11. Juni 2026 läuft, mit Einzelhandelspreisen zwischen $542.16 und $550.21. Nach diesen Transaktionen besitzt Rosa direkt 234,256 Aktien. Die ausgeübte Option, gewährt im Rahmen des 2010 Incentive Award Plan, hat ein Verfallsdatum von 15.02.2027 und war gemäß einem festgelegten Zeitplan vestet.

Intuitive Surgical (ISRG) رئيسها التنفيذي ديفيد ج. روزا أبلغ عن معاملات داخلية في 24/10/2025. قام بممارسة 27,000 خيار شراء غير مؤهل بسعر تنفيذ قدره $79.6378 لكل سهم وببيع 24,500 سهماً من الأسهم العادية بسعر $547.5502 المتوسط المرجح للسهم.

تم تنفيذ هذه المبيعات بموجب خطة تداول Rule 10b5-1 التي تنتهي في 11 يونيو 2026، وبأسعار صفقات فردية تتراوح بين $542.16 و$550.21. عقب هذه المعاملات، يملك روزا مباشرةً 234,256 سهماً من الأسهم. الخيار الممارس، الممنوح بموجب 2010 Incentive Award Plan، له تاريخ انتهاء 15/02/2027 ولم يفلس حسب الجدول المذكور.

Intuitive Surgical (ISRG) 的首席执行官David J. Rosa 在 2025-10-24 披露了内部交易。他以 $79.6378 的执行价行使了 27,000份非合格股票期权,并以 $547.5502 的加权平均价格出售了 24,500 股普通股

这些出售是按照在有效期至 2026-06-11 Rule 10b5-1 交易计划执行的,单笔交易价格在 $542.16$550.21 之间。交易完成后,Rosa 直接持有 234,256 股。该行使的期权是在 2010 Incentive Award Plan 下授予,到期日为 2027-02-15,并按规定的计划归属。

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Rosa David J.

(Last) (First) (Middle)
1020 KIFER ROAD

(Street)
SUNNYVALE CA 94086

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
INTUITIVE SURGICAL INC [ ISRG ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
X Officer (give title below) Other (specify below)
Chief Executive Officer (CEO)
3. Date of Earliest Transaction (Month/Day/Year)
10/24/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 10/24/2025 M(1) 27,000 A $79.6378 258,756 D
Common Stock 10/24/2025 S(1) 24,500 D $547.5502(2) 234,256 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Non-Qualified Stock Option (right to buy) $79.6378 10/24/2025 M(1) 27,000 (3) 02/15/2027 Common Stock 27,000 $0.0 0 D
Explanation of Responses:
1. The transaction took place in accordance with a Trading Plan that complies with SEC Rule 10b5-1 and expires on June 11, 2026.
2. The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $542.16 to $550.21 as follows: 1,075 shares sold at $542.16 to $543.10; 1,000 shares sold at $543.23 to $544.22; 1,830 shares sold at $544.30 to $545.06; 1,300 shares sold at $545.33 to $546.15; 2,346 shares sold at $546.34 to $547.30; 6,919 shares sold at $547.37 to $548.37; 7,257 shares sold at $548.40 to $549.40; and 2,773 shares sold at $549.42 to $550.21. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
3. Non-statutory stock option granted pursuant to the 2010 Incentive Award Plan. The option vests 1/8th six months after the date of grant and 1/48th monthly thereafter.
By: Stephanie Lim-Ignacio For: Rosa, David J 10/27/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did ISRG’s CEO report on Form 4?

David J. Rosa exercised 27,000 options at $79.6378 and sold 24,500 shares at a $547.5502 weighted average price on 10/24/2025.

Were the ISRG stock sales under a 10b5-1 plan?

Yes. The sales were made under a Rule 10b5-1 trading plan that expires on June 11, 2026.

What price range did the ISRG share sales occur at?

Multiple trades occurred between $542.16 and $550.21, resulting in a weighted average of $547.5502.

How many ISRG shares does the CEO own after the transactions?

Following the reported transactions, Rosa beneficially owns 234,256 shares directly.

What options did the CEO exercise?

He exercised non-qualified stock options for 27,000 shares at $79.6378, granted under the 2010 Incentive Award Plan, expiring on 02/15/2027.

When did the ISRG insider transactions occur?

All reported transactions occurred on 10/24/2025.
Intuitive Surgical Inc

NASDAQ:ISRG

ISRG Rankings

ISRG Latest News

ISRG Latest SEC Filings

ISRG Stock Data

193.74B
352.24M
0.53%
89.01%
1.52%
Medical Instruments & Supplies
Orthopedic, Prosthetic & Surgical Appliances & Supplies
Link
United States
SUNNYVALE